These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 35891800)

  • 21. Cathelicidins and defensins antimicrobial host defense peptides in the treatment of TB and HIV: Pharmacogenomic and nanomedicine approaches towards improved therapeutic outcomes.
    Dlozi PN; Gladchuk A; Crutchley RD; Keuler N; Coetzee R; Dube A
    Biomed Pharmacother; 2022 Jul; 151():113189. PubMed ID: 35676789
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Recent progress in mycobacteriology].
    Okada M; Kobayashi K
    Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Designing α-helical peptides with enhanced synergism and selectivity against Mycobacterium smegmatis: Discerning the role of hydrophobicity and helicity.
    Khara JS; Lim FK; Wang Y; Ke XY; Voo ZX; Yang YY; Lakshminarayanan R; Ee PLR
    Acta Biomater; 2015 Dec; 28():99-108. PubMed ID: 26380930
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structural and functional swapping of amyloidogenic and antimicrobial peptides: Redefining the role of amyloidogenic propensity in disease and host defense.
    Yadav JK
    J Pept Sci; 2022 Apr; 28(4):e3378. PubMed ID: 34738279
    [TBL] [Abstract][Full Text] [Related]  

  • 25.
    Bobde SS; Alsaab FM; Wang G; Van Hoek ML
    Front Microbiol; 2021; 12():715246. PubMed ID: 34867843
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acyldepsipeptide Analogues: A Future Generation Antibiotics for Tuberculosis Treatment.
    Cobongela SZZ; Makatini MM; Mdluli PS; Sibuyi NRS
    Pharmaceutics; 2022 Sep; 14(9):. PubMed ID: 36145704
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-mycobacterial activities of synthetic cationic α-helical peptides and their synergism with rifampicin.
    Khara JS; Wang Y; Ke XY; Liu S; Newton SM; Langford PR; Yang YY; Ee PL
    Biomaterials; 2014 Feb; 35(6):2032-8. PubMed ID: 24314557
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antimicrobial peptides: key components of the innate immune system.
    Pasupuleti M; Schmidtchen A; Malmsten M
    Crit Rev Biotechnol; 2012 Jun; 32(2):143-71. PubMed ID: 22074402
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antimicrobial peptides as an alternative to anti-tuberculosis drugs.
    AlMatar M; Makky EA; Yakıcı G; Var I; Kayar B; Köksal F
    Pharmacol Res; 2018 Feb; 128():288-305. PubMed ID: 29079429
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alternative Antibiotics in Dentistry: Antimicrobial Peptides.
    Griffith A; Mateen A; Markowitz K; Singer SR; Cugini C; Shimizu E; Wiedman GR; Kumar V
    Pharmaceutics; 2022 Aug; 14(8):. PubMed ID: 36015305
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mammalian Antimicrobial Peptides: Promising Therapeutic Targets Against Infection and Chronic Inflammation.
    Dutta P; Das S
    Curr Top Med Chem; 2016; 16(1):99-129. PubMed ID: 26139111
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibacterial Properties and Efficacy of a Novel SPLUNC1-Derived Antimicrobial Peptide, α4-Short, in a Murine Model of Respiratory Infection.
    Jiang S; Deslouches B; Chen C; Di ME; Di YP
    mBio; 2019 Apr; 10(2):. PubMed ID: 30967458
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A review on anti-tuberculosis peptides: Impact of peptide structure on anti-tuberculosis activity.
    Yathursan S; Wiles S; Read H; Sarojini V
    J Pept Sci; 2019 Nov; 25(11):e3213. PubMed ID: 31515916
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antimicrobial activity of synthetic antimicrobial peptides loaded in poly-Ɛ-caprolactone nanoparticles against mycobacteria and their functional synergy with rifampicin.
    Sharma A; Gaur A; Kumar V; Sharma N; Patil SA; Verma RK; Singh AK
    Int J Pharm; 2021 Oct; 608():121097. PubMed ID: 34534632
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antimicrobial Peptides: Features, Action, and Their Resistance Mechanisms in Bacteria.
    Moravej H; Moravej Z; Yazdanparast M; Heiat M; Mirhosseini A; Moosazadeh Moghaddam M; Mirnejad R
    Microb Drug Resist; 2018; 24(6):747-767. PubMed ID: 29957118
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Harnessing Biological Insight to Accelerate Tuberculosis Drug Discovery.
    de Wet TJ; Warner DF; Mizrahi V
    Acc Chem Res; 2019 Aug; 52(8):2340-2348. PubMed ID: 31361123
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immuno-Stimulatory Peptides as a Potential Adjunct Therapy against Intra-Macrophagic Pathogens.
    Silva T; Gomes MS
    Molecules; 2017 Aug; 22(8):. PubMed ID: 28777342
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antimicrobial Peptide Exposure Selects for Resistant and Fit Stenotrophomonas maltophilia Mutants That Show Cross-Resistance to Antibiotics.
    Blanco P; Hjort K; Martínez JL; Andersson DI
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32999081
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synergism between Host Defence Peptides and Antibiotics Against Bacterial Infections.
    Li J; Fernández-Millán P; Boix E
    Curr Top Med Chem; 2020; 20(14):1238-1263. PubMed ID: 32124698
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antimicrobial Peptides: Vestiges of Past or Modern Therapeutics?
    Mitra JB; Sharma VK; Kumar M; Mukherjee A
    Mini Rev Med Chem; 2020; 20(3):183-195. PubMed ID: 31774045
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.